Loading...

We've got a brand new version of Simply Wall St! Try it out

Baxter International

SWX:BAX
Snowflake Description

Outstanding track record with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BAX
SWX
$41B
Market Cap
  1. Home
  2. CH
  3. Healthcare
Company description

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products. The last earnings update was 107 days ago. More info.


Add to Portfolio Compare Print
BAX Share Price and Events
7 Day Returns
0%
SWX:BAX
0.7%
CH Medical Equipment
-0.4%
CH Market
1 Year Returns
10%
SWX:BAX
33.3%
CH Medical Equipment
12.3%
CH Market
BAX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Baxter International (BAX) 0% 0% 0% 10% 88.5% 15.1%
CH Medical Equipment 0.7% 2.5% 4.3% 33.3% 85.6% 109.4%
CH Market -0.4% 2.6% 6.7% 12.3% 21.5% 13.4%
1 Year Return vs Industry and Market
  • BAX underperformed the Medical Equipment industry which returned 33.3% over the past year.
  • BAX underperformed the Market in Switzerland which returned 12.3% over the past year.
Price Volatility
BAX
Industry
5yr Volatility vs Market

Value

 Is Baxter International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Baxter International to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Baxter International.

SWX:BAX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 17 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9%
Perpetual Growth Rate 10-Year CH Government Bond Rate 3.3%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for SWX:BAX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CH Govt Bond Rate 3.3%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.84
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.84 (1 + (1- 21%) (14.01%))
0.955
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.96
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 3.28% + (0.955 * 5.96%)
8.97%

Discounted Cash Flow Calculation for SWX:BAX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Baxter International is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

SWX:BAX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.97%)
2020 1,957.50 Analyst x2 1,796.42
2021 2,139.75 Analyst x4 1,802.08
2022 2,275.50 Analyst x2 1,758.70
2023 2,426.50 Analyst x2 1,721.08
2024 2,550.77 Est @ 5.12% 1,660.34
2025 2,667.27 Est @ 4.57% 1,593.30
2026 2,778.75 Est @ 4.18% 1,523.30
2027 2,887.35 Est @ 3.91% 1,452.58
2028 2,994.71 Est @ 3.72% 1,382.61
2029 3,102.08 Est @ 3.59% 1,314.33
Present value of next 10 years cash flows $16,004.00
SWX:BAX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $3,102.08 × (1 + 3.28%) ÷ (8.97% – 3.28%)
$56,284.02
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $56,284.02 ÷ (1 + 8.97%)10
$23,847.12
SWX:BAX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $16,004.00 + $23,847.12
$39,851.12
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $39,851.12 / 510.56
$78.05
SWX:BAX Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in SWX:BAX represents 0.95203x of NYSE:BAX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.95203x
Value per Share
(Listing Adjusted, CHF)
= Value per Share (USD) x Listing Adjustment Factor
= $ 78.05 x 0.95203
CHF74.31
Value per share (CHF) From above. CHF74.31
Current discount Discount to share price of CHF77.00
= -1 x (CHF77.00 - CHF74.31) / CHF74.31
-3.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Baxter International is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Baxter International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Baxter International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
SWX:BAX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in USD $3.05
NYSE:BAX Share Price ** NYSE (2019-11-13) in USD $80.88
Switzerland Medical Equipment Industry PE Ratio Median Figure of 7 Publicly-Listed Medical Equipment Companies 33.29x
Switzerland Market PE Ratio Median Figure of 171 Publicly-Listed Companies 19.37x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Baxter International.

SWX:BAX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:BAX Share Price ÷ EPS (both in USD)

= 80.88 ÷ 3.05

26.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Baxter International is good value based on earnings compared to the CH Medical Equipment industry average.
  • Baxter International is overvalued based on earnings compared to the Switzerland market.
Price based on expected Growth
Does Baxter International's expected growth come at a high price?
Raw Data
SWX:BAX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 26.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts
11.2%per year
Switzerland Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.34x
Switzerland Market PEG Ratio Median Figure of 124 Publicly-Listed Companies 2.14x

*Line of best fit is calculated by linear regression .

SWX:BAX PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 26.54x ÷ 11.2%

2.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Baxter International is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Baxter International's assets?
Raw Data
SWX:BAX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in USD $15.31
NYSE:BAX Share Price * NYSE (2019-11-13) in USD $80.88
Switzerland Medical Equipment Industry PB Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 6.21x
Switzerland Market PB Ratio Median Figure of 214 Publicly-Listed Companies 1.65x
SWX:BAX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:BAX Share Price ÷ Book Value per Share (both in USD)

= 80.88 ÷ 15.31

5.28x

* Primary Listing of Baxter International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Baxter International is good value based on assets compared to the CH Medical Equipment industry average.
X
Value checks
We assess Baxter International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Baxter International has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Baxter International expected to perform in the next 1 to 3 years based on estimates from 17 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Baxter International expected to grow at an attractive rate?
  • Baxter International's earnings growth is expected to exceed the low risk savings rate of 3.3%.
Growth vs Market Checks
  • Baxter International's earnings growth is expected to exceed the Switzerland market average.
  • Baxter International's revenue growth is expected to exceed the Switzerland market average.
Annual Growth Rates Comparison
Raw Data
SWX:BAX Future Growth Rates Data Sources
Data Point Source Value (per year)
SWX:BAX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts 11.2%
SWX:BAX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 17 Analysts 4.8%
Switzerland Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 38.7%
Switzerland Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 7.3%
Switzerland Market Earnings Growth Rate Market Cap Weighted Average 9.9%
Switzerland Market Revenue Growth Rate Market Cap Weighted Average 3.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
SWX:BAX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
SWX:BAX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 13,779 3,322 1
2022-12-31 12,998 3,130 3
2021-12-31 12,424 2,892 2,021 10
2020-12-31 11,797 2,693 1,812 17
2019-12-31 11,281 2,295 1,577 15
2019-11-14
SWX:BAX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-06-30 11,080 1,855 1,588
2019-03-31 11,082 1,791 1,588
2018-12-31 11,127 2,096 1,630
2018-09-30 11,060 1,855 1,215
2018-06-30 11,000 1,971 919
2018-03-31 10,763 2,095 840
2017-12-31 10,561 1,837 724
2017-09-30 10,432 2,036 1,025
2017-06-30 10,283 1,963 904
2017-03-31 10,263 2,176 1,852
2016-12-31 10,163 1,654 4,966
2016-09-30 10,121 1,665 4,909

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Baxter International's earnings are expected to grow by 11.2% yearly, however this is not considered high growth (20% yearly).
  • Baxter International's revenue is expected to grow by 4.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
SWX:BAX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below

All data from Baxter International Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:BAX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 3.95 3.95 3.94 2.00
2020-12-31 3.53 3.69 3.44 4.00
2019-12-31 3.06 3.18 2.96 4.00
2019-11-14
SWX:BAX Past Financials Data
Date (Data in USD Millions) EPS *
2019-06-30 3.05
2019-03-31 3.01
2018-12-31 3.05
2018-09-30 2.26
2018-06-30 1.70
2018-03-31 1.55
2017-12-31 1.33
2017-09-30 1.89
2017-06-30 1.66
2017-03-31 3.40
2016-12-31 9.10
2016-09-30 8.97

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Baxter International is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Baxter International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Switzerland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Switzerland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Baxter International has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Baxter International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Baxter International's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Baxter International's year on year earnings growth rate has been positive over the past 5 years, however the most recent earnings are below average.
  • Baxter International's 1-year earnings growth exceeds its 5-year average (72.8% vs 5.6%)
  • Baxter International's earnings growth has exceeded the CH Medical Equipment industry average in the past year (72.8% vs -9.5%).
Earnings and Revenue History
Baxter International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Baxter International Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

SWX:BAX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 11,080.00 1,588.00 2,363.00 573.00
2019-03-31 11,082.00 1,588.00 2,395.00 596.00
2018-12-31 11,127.00 1,630.00 2,399.00 619.00
2018-09-30 11,060.00 1,215.00 2,463.00 635.00
2018-06-30 11,000.00 919.00 2,507.00 631.00
2018-03-31 10,763.00 840.00 2,478.00 621.00
2017-12-31 10,561.00 724.00 2,457.00 613.00
2017-09-30 10,432.00 1,025.00 2,424.00 584.00
2017-06-30 10,283.00 904.00 2,382.00 564.00
2017-03-31 10,263.00 1,852.00 2,447.00 560.00
2016-12-31 10,163.00 4,966.00 2,520.00 566.00
2016-09-30 10,121.00 4,909.00 2,566.00 573.00
2016-06-30 10,050.00 4,784.00 2,625.00 584.00
2016-03-31 9,940.00 3,646.00 2,704.00 582.00
2015-12-31 9,968.00 393.00 2,832.00 589.00
2015-09-30 10,154.00 337.00 2,972.00 585.00
2015-06-30 10,376.00 510.00 3,087.00 593.00
2015-03-31 9,274.00 84.00 3,037.00 473.00
2014-12-31 10,719.00 457.00 3,182.00 608.00
2014-09-30 12,252.00 739.00 3,301.00 743.00
2014-06-30 13,253.00 1,092.00 3,334.00 847.00
2014-03-31 15,367.00 1,967.00 3,437.00 1,047.00
2013-12-31 9,413.00 315.00 2,859.00 534.00
2013-09-30 14,398.00 2,097.00 3,314.00 876.00
2013-06-30 14,165.00 2,152.00 3,239.00 914.00
2013-03-31 14,250.00 2,290.00 3,233.00 992.00
2012-12-31 13,936.00 2,283.00 3,044.00 940.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Baxter International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Baxter International used its assets more efficiently than the CH Medical Equipment industry average last year based on Return on Assets.
  • Baxter International has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Baxter International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Baxter International has a total score of 6/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Baxter International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Baxter International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Baxter International is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Baxter International's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Baxter International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Baxter International Company Filings, last reported 4 months ago.

SWX:BAX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 7,836.00 5,139.00 2,925.00
2019-03-31 7,669.00 4,205.00 1,908.00
2018-12-31 7,816.00 3,477.00 1,832.00
2018-09-30 9,113.00 3,488.00 2,860.00
2018-06-30 8,869.00 3,498.00 2,857.00
2018-03-31 9,093.00 3,553.00 2,947.00
2017-12-31 9,116.00 3,512.00 3,394.00
2017-09-30 9,459.00 3,498.00 3,517.00
2017-06-30 9,165.00 3,457.00 3,817.00
2017-03-31 8,675.00 2,787.00 2,858.00
2016-12-31 8,280.00 2,782.00 2,801.00
2016-09-30 8,664.00 2,840.00 2,597.00
2016-06-30 8,510.00 3,168.00 2,630.00
2016-03-31 9,020.00 3,357.00 3,443.00
2015-12-31 8,865.00 6,507.00 7,361.00
2015-09-30 7,845.00 6,729.00 6,126.00
2015-06-30 8,021.00 14,230.00 6,680.00
2015-03-31 7,288.00 10,061.00 2,530.00
2014-12-31 8,156.00 9,029.00 2,925.00
2014-09-30 8,426.00 9,275.00 2,078.00
2014-06-30 8,687.00 8,839.00 1,866.00
2014-03-31 8,693.00 8,695.00 2,049.00
2013-12-31 8,486.00 9,290.00 2,733.00
2013-09-30 7,746.00 9,066.00 2,376.00
2013-06-30 7,315.00 9,035.00 5,989.00
2013-03-31 7,001.00 5,869.00 2,692.00
2012-12-31 6,978.00 5,930.00 3,270.00
  • Baxter International's level of debt (65.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (101.8% vs 65.6% today).
  • Debt is well covered by operating cash flow (36.1%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 30.6x coverage).
X
Financial health checks
We assess Baxter International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Baxter International has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Baxter International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.09%
Current annual income from Baxter International dividends. Estimated to be 1.17% next year.
If you bought CHF2,000 of Baxter International shares you are expected to receive CHF22 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Baxter International's pays a lower dividend yield than the bottom 25% of dividend payers in Switzerland (1.85%).
  • Baxter International's dividend is below the markets top 25% of dividend payers in Switzerland (3.63%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
SWX:BAX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
Switzerland Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 1%
Switzerland Market Average Dividend Yield Market Cap Weighted Average of 163 Stocks 2.9%
Switzerland Minimum Threshold Dividend Yield 10th Percentile 1.2%
Switzerland Bottom 25% Dividend Yield 25th Percentile 1.8%
Switzerland Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

SWX:BAX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31 1.17 1.00
2021-12-31 1.06 5.00
2020-12-31 0.95 8.00
2019-12-31 0.82 6.00
2019-11-14
SWX:BAX Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-07-16 0.880 1.039
2019-05-07 0.880 1.124
2019-02-19 0.760 0.987
2018-11-13 0.760 1.125
2018-07-17 0.760 1.058
2018-05-08 0.760 1.040
2018-02-20 0.640 0.955
2017-11-14 0.640 0.964
2017-07-18 0.640 1.023
2017-05-02 0.640 1.087
2017-02-21 0.520 0.996
2016-11-08 0.520 1.126
2016-07-19 0.520 1.097
2016-05-03 0.520 1.161
2016-02-16 0.460 1.123
2015-11-10 0.460 1.241
2015-07-29 0.460 1.254
2015-05-05 2.080 3.871
2015-02-17 2.080 3.014
2014-11-11 2.080 2.885
2014-07-22 2.080 2.858
2014-05-05 2.080 2.791
2014-02-18 1.960 2.778
2013-11-12 1.960 2.868
2013-07-23 1.960 2.841
2013-05-06 1.960 2.762
2013-02-19 1.800 2.579
2012-11-13 1.800 2.684
2012-07-25 1.800 2.978
2012-05-07 1.340 2.549
2012-02-21 1.340 2.330
2011-11-15 1.340 2.579
2011-07-26 1.240 2.269
2011-05-02 1.240 2.088
2011-02-15 1.240 2.320
2010-11-09 1.240 2.468
2010-07-27 1.160 2.483
2010-05-04 1.160 2.723
2010-02-16 1.160 2.058
2009-11-10 1.160 2.019
2009-07-28 1.040 1.854
2009-05-05 1.040 2.047
2009-02-17 1.040 2.036

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Baxter International is not paying a notable dividend for Switzerland, therefore no need to check if the payments are stable.
  • Baxter International is not paying a notable dividend for Switzerland, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of Baxter International's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of Baxter International's dividends as it is not paying a notable one for Switzerland.
Future Payout to shareholders
  • No need to calculate the sustainability of Baxter International's dividends in 3 years as they are not expected to pay a notable one for Switzerland.
X
Income/ dividend checks
We assess Baxter International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Baxter International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Baxter International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Baxter International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joe Almeida
COMPENSATION $15,645,125
AGE 57
TENURE AS CEO 3.8 years
CEO Bio

Mr. José E. Almeida, also known as Joe, has been the Chairman and Chief Executive Officer of Baxter International Inc. since January 1, 2016 and serves as its President. Mr. Almeida has been Director at Baxter International Inc. since January 2016. He has more than 25 years of experience in health care, including medical devices, consumer health products, surgical instruments and biopharmaceuticals. He served as Senior Advisor with The Carlyle Group from May 2015 until October 2015. He served as an Operating Executive in the Global Healthcare group at The Carlyle Group LP from May 4, 2015 to October 2015. Mr. Almeida served as Chief Executive Officer at Baxter International Inc. from October 28, 2015 to November 20, 2015 and served as its Corporate Vice President since November 20, 2015. He was part of the U.S. buyout asset class. As an Operating Executive, Mr. Almeida provides strategic guidance and advice to Carlyle professionals and portfolio company executives on prospective investments, overall business strategy and value creation opportunities within the healthcare industry. He served as the Chief Executive Officer of Covidien PLC from July 1, 2011 to 2015 and served as its President since July 1, 2011. He served as the Chairman of the Board of Covidien PLC since March 13, 2012 till January 2015. Mr. Almeida was employed at Tyco International Ltd. and Tyco International plc. He joined Covidien in 1995 and held leadership positions in global manufacturing and corporate engineering. Mr. Almeida served as the President of Medical Devices at Covidien plc from October 2006 to June 2011. Mr. Almeida served as a Senior Vice President of Covidien plc since June 2007. Mr. Almeida served as the Vice President of Worldwide Manufacturing at Tyco Healthcare from 2000 to 2002, Vice President of Manufacturing at Tyco Healthcare Europe, Middle East and Africa from 1998 to 2002 and Director of Manufacturing and Corporate Engineering from 1998 to 2000. He served as the President of Tyco Healthcare's International Business from April 2004 to October 2006. He served as an Executive Vice President and Chief Operating Officer of Integer Holdings Corporation from January 2003 to April 01, 2004. Mr. Almeida served with Acufex Medical, Johnson & Johnson Professional, Inc. and Andersen Consulting (Accenture). He has been an Independent Director of Walgreens Boots Alliance, Inc. since April 19, 2017. He served as a Director of Analog Devices, Inc., from January 20, 2015 to November 06, 2015. He served as a Director of TransMedics, Inc. since October 2007. Mr. Almeida serves on the board of directors of Advanced Medical Technology Association (AdvaMed) and Partners in Health. He serves as a Director of Ortho-Clinical Diagnostics, Inc. He served as Independent Director of State Street Corporation from October 2013 to October 2015. He served as a Director of Dell EMC (alternate name, EMC Corporation) from January 12, 2015 to October 31, 2015. He served as a Director of Covidien PLC from July 1, 2011 to January 2015. He served as the Chairman of the Advanced Medical Technology Association. He has experience in medical technology, in vitro diagnostics, life science tools and pharmaceutical products and services. He received a Bachelor of Science in Mechanical Engineering from Escola de Engenharia Maua in São Paulo, Brazil (Instituto Mauá de Tecnologia in São Paulo).

CEO Compensation
  • Joe's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Joe's remuneration is higher than average for companies of similar size in Switzerland.
Management Team Tenure

Average tenure and age of the Baxter International management team in years:

2.8
Average Tenure
54
Average Age
  • The tenure for the Baxter International management team is about average.
Management Team

Joe Almeida

TITLE
Chairman
COMPENSATION
$16M
AGE
57
TENURE
3.8 yrs

Jay Saccaro

TITLE
Executive VP & CFO
COMPENSATION
$5M
AGE
46
TENURE
4.4 yrs

Sean B. Martin

TITLE
Senior VP & General Counsel
COMPENSATION
$3M
AGE
56
TENURE
2.8 yrs

Giuseppe Accogli

TITLE
Senior VP & President of Americas
COMPENSATION
$4M
AGE
48
TENURE
2.5 yrs

Brian Stevens

TITLE
Senior VP
AGE
44
TENURE
1 yrs

Sumant Ramachandra

TITLE
President of Pharmaceuticals and Senior Vice President
AGE
50
TENURE
2.8 yrs

Paul Martin

TITLE
Chief Information Officer & Senior VP
AGE
61
TENURE
8.8 yrs

Clare Trachtman

TITLE
Vice President of Investor Relations

Jeanne Mason

TITLE
Senior Vice President of Human Resources
COMPENSATION
$4M
AGE
63
TENURE
2.5 yrs

Andrew Frye

TITLE
Senior VP & President of APAC
AGE
54
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the Baxter International board of directors in years:

6.3
Average Tenure
69
Average Age
  • The tenure for the Baxter International board of directors is about average.
Board of Directors

Joe Almeida

TITLE
Chairman
COMPENSATION
$16M
AGE
57
TENURE
3.8 yrs

Bob Parkinson

TITLE
Chairman Emeritus
COMPENSATION
$18M
AGE
68
TENURE
3.8 yrs

James R. Gavin

TITLE
Independent Director
COMPENSATION
$314K
AGE
73
TENURE
16.8 yrs

John Forsyth

TITLE
Independent Director
COMPENSATION
$303K
AGE
71
TENURE
16.2 yrs

Al Stroucken

TITLE
Independent Director
COMPENSATION
$318K
AGE
71
TENURE
15.2 yrs

Steve Oesterle

TITLE
Independent Director
COMPENSATION
$320K
AGE
67
TENURE
2.8 yrs

Tom Stallkamp

TITLE
Lead Independent Director
COMPENSATION
$368K
AGE
72
TENURE
5.5 yrs

Peter Hellman

TITLE
Independent Director
COMPENSATION
$312K
AGE
69
TENURE
14.7 yrs

Thomas Chen

TITLE
Independent Director
COMPENSATION
$298K
AGE
69
TENURE
7 yrs

Mike Mahoney

TITLE
Independent Director
COMPENSATION
$301K
AGE
54
TENURE
4.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CHF) Value (CHF)
17. May 19 Sell Third Point LLC Company 16. May 19 16. May 19 -5,000,000 CHF77.16 CHF-385,783,055
04. Dec 18 Sell Third Point LLC Company 03. Dec 18 03. Dec 18 -8,000,000 CHF68.45 CHF-547,637,006
X
Management checks
We assess Baxter International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Baxter International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. It also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and by patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

Details
Name: Baxter International Inc.
BAX
Exchange: SWX
Founded: 1931
$40,765,198,573
510,555,869
Website: http://www.baxter.com
Address: Baxter International Inc.
One Baxter Parkway,
Deerfield,
Illinois, 60015,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE BAX Common Stock New York Stock Exchange US USD 02. Jan 1968
DB BTL Common Stock Deutsche Boerse AG DE EUR 02. Jan 1968
SWX BAX Common Stock SIX Swiss Exchange CH CHF 02. Jan 1968
WBAG BAX Common Stock Wiener Boerse AG AT EUR 02. Jan 1968
BMV BAX * Common Stock Bolsa Mexicana de Valores MX MXN 02. Jan 1968
Number of employees
Current staff
Staff numbers
50,000
Baxter International employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/14 20:35
End of day share price update: 2019/11/13 00:00
Last estimates confirmation: 2019/10/30
Last earnings filing: 2019/07/30
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.